hsa

OBHSA（Oxabicycloheptane sulfonamide） is a novel selective estrogen receptor depressant (SERD) that can be used to study breast cancer.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are newly identified endogenous lipids regulated by fasting and high-fat feeding and associated with insulin sensitivity. Structurally, these esters are comprised of a C-16 or C-18 fatty acid (e.g., palmitoleic, palmitic, oleic, or stearic acid) linked to a hydroxylated C-16 or C-18 lipid. 9-PAHSA is a FAHFA in which palmitic acid is esterified to 9-hydroxy stearic acid. PAHSAs are the most abundant forms of FAHFA in serum as well as white and brown adipose tissues of glucose tolerant AG4OX mice, which overexpress Glut4 specifically in adipose tissue. 9-PAHSA is the predominant isomer of PAHSA in wild type and AG4OX mice. It is found in humans and is reduced in the serum and adipose tissues of insulin-resistant humans. 9-PAHSA improves glucose tolerance, stimulates insulin secretion, and has anti-inflammatory effects in mice.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are lipids influenced by dietary changes, playing a crucial role in insulin sensitivity. These compounds typically consist of a C-16 or C-18 fatty acid (for example, palmitoleic, palmitic, oleic, or stearic acid) linked to a hydroxy fatty acid with the same carbon chain length. 13-PAHSA, a derivative where palmitic acid is esterified to 13-hydroxy stearic acid, is notably prevalent in the adipose tissue of glucose-tolerant AG4OX mice, which exhibit enhanced glucose transport via the overexpression of the Glut4 glucose transporter. This observation, along with the metabolic benefits seen from other FAHFAs—including improved glucose tolerance, stimulated insulin secretion, and anti-inflammatory properties—suggests that 13-PAHSA may function as a bioactive lipid beneficial in managing metabolic syndrome and inflammation.

13-OAHSA, a branched fatty acid ester of hydroxy fatty acids (FAHFAs), results from the esterification of oleic acid to 13-hydroxy stearic acid. It represents a significant component of the FAHFA family, most abundantly expressed in the serum of glucose-tolerant AG4OX mice that exhibit adipose tissue-specific overexpression of the Glut4 glucose transporter. Similar to other FAHFAs which are known to enhance glucose tolerance, stimulate insulin secretion, and exert anti-inflammatory effects, 13-OAHSA may play a pivotal role in managing metabolic syndrome and inflammation.

15-SAHSA, a branched fatty acid ester of hydroxy fatty acids (FAHFAs), is recognized for its involvement in metabolic regulation. This compound comprises stearic acid esterified to 5-hydroxy stearic acid and is notably influenced by dietary changes, such as fasting and high-fat consumption, with a link to insulin sensitivity. SAHSA levels are specifically found to be moderately increased in the serum of AG4OX mice, which are characterized by their glucose tolerance through the overexpression of the Glut4 glucose transporter in adipose tissue. Given the established functions of FAHFAs in enhancing glucose tolerance, prompting insulin secretion, and exerting anti-inflammatory properties, 5-SAHSA emerges as a potential bioactive lipid implicated in the management of metabolic syndrome and inflammation.

10(S)-PAHSA is a stereoisomer of 10-PAHSA , an endogenous lipid that belongs to a collection of branched fatty acid esters of hydroxy fatty acids (FAHFAs).

5-PAHSA, a FAHFA formed through the formal condensation of the carboxy group of palmitic acid with the hydroxy group of 5-hydroxystearic acid, serves as a human metabolite, possesses anti-inflammatory and hypoglycemic properties, and is categorized as a long-chain fatty acid. This compound, deriving from hexadecanoic acid and octadecanoic acid, is the conjugate acid of a 5-PAHSA(1-).

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are recently discovered lipids that play a role in the body's response to fasting and high-fat diets, with a link to insulin sensitivity. These compounds consist of a long-chain fatty acid (such as palmitoleic, palmitic, oleic, or stearic acid) bonded to a hydroxy fatty acid, both ranging in length from C-16 to C-18. Specifically, 12-OAHSA is a type of FAHFA where oleic acid is attached to the 12th carbon of hydroxy stearic acid. Within the FAHFA family, OAHSAs are particularly notable for their high concentration in the serum of AG4OX mice, a strain engineered to express the Glut4 glucose transporter predominantly in their adipose tissue, which demonstrates an enhanced glucose tolerance.

13-SAHSA, a branched fatty acid ester of hydroxy fatty acids (FAHFAs), has been found to be involved in metabolic regulation, particularly in relation to fasting, high-fat feeding, and insulin sensitivity. This compound is a synthesis of stearic acid and 13-hydroxy stearic acid. Notably, 13-SAHSA levels are found to be moderately increased in the serum of AG4OX mice, which are characterized by their glucose tolerance and expression of the Glut4 glucose transporter specifically in their adipose tissue. Similar to other FAHFAs, 13-SAHSA is believed to play a significant role in enhancing glucose tolerance, stimulating insulin secretion, and exerting anti-inflammatory effects, indicating its potential importance in addressing conditions related to metabolic syndrome and inflammation.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are endogenous lipids that are influenced by fasting and high-fat diets and linked to improved insulin sensitivity in mice. These compounds typically feature a chain of either 16 or 18 carbon atoms (for example, palmitoleic, palmitic, oleic, or stearic acid) esterified with a hydroxy fatty acid chain of similar length. One specific FAHFA, known as 5-OAHSA, consists of oleic acid bonded to the fifth carbon of hydroxy stearic acid. Within the FAHFA family, OAHSAs exhibit the highest serum levels in AG4OX mice, which are known for their glucose tolerance attributed to the overexpression of the Glut4 glucose transporter in adipose tissue.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) have emerged as significant regulators of metabolic processes, influenced by dietary changes such as fasting and high-fat diets, and are linked to improved insulin sensitivity in mice. These compounds typically feature a fatty acid chain, either C-16 or C-18 in length (for example, palmitoleic, palmitic, oleic, or stearic acid), esterified to a hydroxy fatty acid of similar length. A specific FAHFA, 12-POHSA, involves the esterification of palmitoleic acid to the 12th carbon of stearic acid. Notably, 12-POHSA levels are markedly higher in the serum of AG4OX mice, which exhibit enhanced glucose tolerance due to overexpression of the Glut4 glucose transporter in adipose tissue. Given the capacity of FAHFAs to enhance glucose tolerance, stimulate insulin secretion, and exert anti-inflammatory actions, 12-POHSA holds potential as a bioactive lipid implicated in managing metabolic syndrome and inflammation.

9(R)-PAHSA is a stereoisomer of 9-PAHSA , an endogenous lipid that belongs to a collection of branched fatty acid esters of hydroxy fatty acids (FAHFAs).

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are newly identified endogenous lipids regulated by fasting and high-fat feeding and associated with insulin sensitivity. Structurally, these esters are comprised of a C-16 or C-18 fatty acid (e.g., palmitoleic, palmitic, oleic, or stearic acid) linked to either a C-16 or C-18 hydroxy substituent. 12-PAHSA is a FAHFA in which palmitic acid is esterified at the 12th carbon of hydroxy stearic acid. Among the FAHFA family members, PAHSAs are the most abundant in the adipose tissue of glucose tolerant AG4OX mice, which overexpress the Glut4 glucose transporter specifically in adipose tissue. 12-PAHSA is present at 2- to 3-fold higher levels in adipose tissue of AG4OX mice compared to wild type mice. Levels of 12-PAHSA are also higher in fasted wild-type mice compared to fed mice and are reduced upon high-fat diet-induced obesity in insulin-resistant mice.

13-POHSA (palmitoleic acid esterified to 13-hydroxy stearic acid) is a type of branched fatty acid esters of hydroxy fatty acids (FAHFAs), which have recently been discovered as endogenous lipids whose levels are modulated by fasting and high-fat diets, and are linked to insulin sensitivity in mice. Notably, the concentration of 13-POHSA in the serum significantly increases in glucose tolerant AG4OX mice, a model that overexpresses the Glut4 glucose transporter in adipose tissue, suggesting its physiological relevance. Like other FAHFAs, 13-POHSA is believed to enhance glucose tolerance, promote insulin secretion, and exert anti-inflammatory properties, highlighting its potential importance in managing metabolic syndrome and inflammation.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs), endogenous lipids influenced by fasting and high-fat diets, are linked to improved insulin sensitivity in mice. These molecules consist of a C-16 or C-18 fatty acid (e.g., palmitoleic, palmitic, oleic, or stearic acid) bonded to a C-16 or C-18 hydroxy fatty acid. A specific FAHFA, 5-POHSA, features palmitoleic acid esterified with hydroxy stearic acid at the 5th carbon. Elevated levels of 5-POHSA in the serum of AG4OX mice, which express high levels of the Glut4 glucose transporter in adipose tissue, correlate with glucose tolerance. Like other FAHFAs that enhance glucose tolerance, stimulate insulin secretion, and exhibit anti-inflammatory properties, 5-POHSA may play a role in managing metabolic syndrome and inflammation.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are a class of endogenous lipids whose levels are modulated by fasting and high-fat diets and are linked to insulin sensitivity. These compounds typically consist of a C-16 or C-18 fatty acid, such as palmitoleic, palmitic, oleic, or stearic acid, esterified to a hydroxylated C-16 or C-18 lipid. One specific form of FAHFA, known as 9-OAHSA, involves the esterification of oleic acid to 9-hydroxy stearic acid. Within the FAHFA family, OAHSAs notably represent the predominant form found in the serum of glucose-tolerant AG4OX mice, which uniquely overexpress the Glut4 glucose transporter in adipose tissue.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are recent discoveries in endogenous lipids that are influenced by dietary changes such as fasting and high-fat diets, showing a link with enhanced insulin sensitivity in mice. These compounds typically feature a C-16 or C-18 fatty acid (e.g., palmitoleic, palmitic, oleic, or stearic acid) bound to a hydroxy group on another C-16 or C-18 fatty chain. A specific FAHFA, 9-POHSA, consists of palmitoleic acid connected at the hydroxy stearic acid’s 9th position. This molecule, in particular, exhibits notably increased levels in the serum of glucose-tolerant AG4OX mice, which express the Glut4 glucose transporter predominantly in their adipose tissue. Given the broader family of FAHFAs' roles in enhancing glucose tolerance, promoting insulin secretion, and exerting anti-inflammatory effects, 9-POHSA emerges as a potential bioactive lipid involved in managing metabolic syndrome and inflammation.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are lipids that are modulated by dietary changes such as fasting and high-fat diets, and they play a role in insulin sensitivity. These compounds generally consist of a fatty acid chain of either 16 or 18 carbons (for example, palmitoleic, palmitic, oleic, or stearic acid) esterified to a similarly long hydroxy fatty acid. One specific FAHFA, 9-SAHSA, features stearic acid esterified at the 9th carbon of hydroxy stearic acid. The concentration of 9-SAHSA is notably increased in the serum of glucose-tolerant AG4OX mice, which specifically express the Glut4 glucose-transporting protein in adipose tissue.

10-PAHSA is a newly identified endogenous lipid that belongs to a collection of branched fatty acid esters of hydroxy fatty acids (FAHFAs). It is a FAHFA in which palmitic acid is esterified to 10-hydroxy stearic acid. Among the FAHFA family members, PAHSAs are the most abundant in the adipose tissue of glucose tolerant AG4OX mice, which overexpress the Glut4 glucose transporter specifically in adipose tissue. As other FAHFAs improve glucose tolerance, stimulate insulin secretion, and have anti-inflammatory effects, 10-PAHSA may be a bioactive lipid with roles in metabolic syndrome and inflammation.

10(R)-PAHSA is a stereoisomer of 10-PAHSA , an endogenous lipid that belongs to a collection of branched fatty acid esters of hydroxy fatty acids (FAHFAs).

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are lipids recently discovered to be modulated by dietary influences such as fasting and high-fat feeding, and they play a role in enhancing insulin sensitivity. These compounds typically feature a carbon-16 or carbon-18 fatty acid (e.g., palmitoleic, palmitic, oleic, or stearic acid) esterified to a carbon-16 or carbon-18 hydroxy fatty acid. A specific example is 12-SAHSA, which consists of stearic acid linked to 12-hydroxy stearic acid. Notably, 12-SAHSA levels are found to be moderately increased in the serum of glucose tolerant AG4OX mice, a model characterized by adipose tissue-specific overexpression of the Glut4 glucose transporter.

Branched fatty acid esters of hydroxy fatty acids (FAHFAs) are a class of endogenous lipids whose levels are modulated by fasting and high-fat diets, and they play a role in insulin sensitivity. These compounds consist of a fatty acid—either a C-16 or C-18, such as palmitoleic, palmitic, oleic, or stearic acid—esterified to a hydroxylated C-16 or C-18 lipid. One notable FAHFA, 9-PAHSA, features an ester linkage between palmitic acid and 9-hydroxy stearic acid. PAHSAs, with 9-PAHSA being the most prevalent isomer, are significantly found in the serum and both white and brown adipose tissues of glucose-tolerant AG4OX mice, which express the Glut4 gene in adipose tissue, enhancing insulin sensitivity. Additionally, 9-PAHSA is abundant in wild type and AG4OX mice and present in humans, though at reduced levels in those with insulin resistance. 9-PAHSA is associated with improved glucose tolerance, enhanced insulin secretion, and anti-inflammatory effects in mice. The compound 19-PAHSA^13C4 represents an isotopically enriched form of this polyunsaturated fatty acid.

10-OAHSA is a newly discovered endogenous lipid categorized within the group of branched fatty acid esters of hydroxy fatty acids (FAHFAs). This specific FAHFA comprises oleic acid esterified to 10-hydroxy stearic acid. It stands out among its FAHFA counterparts for its potential bioactive properties, similar to other members of its family such as PAHSAs, which are notably prevalent in the adipose tissue of AG4OX mice exhibiting glucose tolerance due to overexpression of the Glut4 glucose transporter specifically in adipose tissue. Like other FAHFAs, 10-OAHSA may play significant roles in enhancing glucose tolerance, stimulating insulin secretion, and exerting anti-inflammatory effects, which suggests its importance in managing metabolic syndrome and inflammation.

10-SAHSA, an endogenous lipid recently discovered, is part of the FAHFAs, a group of branched fatty acid esters of hydroxy fatty acids. It specifically consists of stearic acid esterified to 10-hydroxy stearic acid. Notably, PAHSAs, closely related to 10-SAHSA, are significantly present in the adipose tissue of AG4OX mice that are glucose tolerant due to the overexpression of the Glut4 glucose transporter in their adipose tissue. Similar to other FAHFAs, which are known to improve glucose tolerance, promote insulin secretion, and possess anti-inflammatory properties, 10-SAHSA is considered a potential bioactive lipid with implications for metabolic syndrome and inflammation management.

1-Palmitoyl-2-12-PAHSA-3-oleoyl-sn-glycerol, an endogenous triacylglycerol, comprises palmitic acid (at the sn-1 position), the fatty acid ester of hydroxy fatty acids (FAHFA), 12-PAHSA (at the sn-2 position), and oleic acid (at the sn-3 position). Identified in the lipid extract of mouse adipose tissue, this triacylglycerol demonstrates that levels of FAHFA-containing triacylglycerols are over 100-fold higher than those of non-esterified FAHFAs, suggesting their role as intracellular storage reservoirs for FAHFAs.

Dazodalibep (MEDI 4920; VIB 4920) is a monoclonal antibody that specifically targets CD40LG/TNFSF5 and is fused to human serum albumin (ALB/HSA) [1].

4-epi-Withaferin A (compound 28), an analogue of Withaferin A, exhibits enhanced cytotoxicity and cytoprotective heat-shock-inducing activity (HSA). It shows promise for the investigation of protein aggregation-associated diseases through the stimulation of cellular defense mechanisms [1].

Ozoralizumab (ATN-103), a humanized trivalent nanobody compound, comprises two anti-human TNFα nanobodies along with an anti-human serum albumin (HSA) nanobody, acting as an anti-TNFα humanized antibody. This compound is utilized in the research of arthritis [1].

There is a synergistic interaction between loureirin A and Cochinchinenin C, and the fluorescence quenching of HSA by loureirin A (or Cochinchinenin C) is a combined quenching procedure (dynamic and static quenching).

Paclitaxel octadecanedioate is a prodrug form of paclitaxel that is comprised of paclitaxel conjugated to 1,18-octadecanedioic acid.1 Unlike paclitaxel, it does not promote tubulin polymerization in vitro when used at a concentration of 10 μM. A 5:1 mixture of paclitaxel octadecanedioate:human serum albumin (HSA) is cytotoxic to HT-1080, PANC-1, and HT-29 cells (IC50s = 12, 2.48, and 8.62 nM, respectively). This mixture reduces tumor growth and increases survival in an HT-1080 mouse xenograft model in a dose-dependent manner. |1. Callmann, C.E., Leguyader, C.L.M., Burton, S.T., et al. Antitumor activity of 1,18-octadecanedioic acid-paclitaxel complexed with human serum albumin. J. Am. Chem. Soc. 141(30), 11765-11769 (2019).

Pep2 peptide, a peptide ligand for CD36 (transmembrane glycoprotein or scavenger receptor B2), exhibits selective binding to CD36 over human serum albumin (HSA), IgG, and CD44 in cell-free assays at 1 mM concentration. Pep2 peptide-functionalized micelles, when loaded with the anticancer agent doxorubicin, significantly enhance the cellular uptake and cytotoxicity of doxorubicin in HepG2 hepatocellular carcinoma cells that overexpress CD36, compared to micelles without Pep2 peptide.

DOTA-NHS-ester is a linker of affibody molecules for small animal PET, SPECT and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for tumor detection.

Antibacterial Agent 144 (compound 8e) exhibits superior efficacy against multi-resistant Staphylococcus aureus compared to Chloromycin and Amoxicillin. It acts by disrupting the bacterial cytoplasmic membrane and inhibiting biofilm formation. Additionally, it binds to human serum albumin (HSA) with a dissociation constant (Kd) of 13.2 μM, enhancing its bactericidal activity. This compound also forms a supramolecular complex with DNA, thereby hindering DNA replication [1].

Regavirumab (MCA C23), a human monoclonal antibody, targets cytomegalovirus (CMV), human serum albumin (HSA), and amino acetic acid [1].

Streptochlorin is a bacterial metabolite originally isolated from Streptomyces sp. SF2583 that has diverse biological activities, including antiangiogenic, antiproliferative, and anti-allergic properties. It inhibits TNF-α-induced NF-κB transcriptional activity and decreases proliferation of human umbilical vein endothelial cells (HUVECs) when used at concentrations ranging from 5 to 20 μM. Streptochlorin (12 μg/ml) decreases viability of, as well as induces apoptosis and increases the production of reactive oxygen species (ROS) in, Hep3B human hepatocellular carcinoma cells. It does not induce cytotoxicity in RBL-2H3 mast cells at concentrations up to 100 μM. Streptochlorin prevents degranulation in antigen-stimulated mast cells, as well as inhibits Syk kinase and the Src family kinases LYN and Fyn and reduces the secretion of TNF-α and IL-4 induced by dinitrophenyl-human serum album (DNP-HSA) in RBL-2H3 mast cells. It also decreases swelling and reduces scratching behavior in a mouse model of allergic dermatitis induced by dinitrofluorobenzene (DNFB).

Albumin blue 670, as an Albumin probe, can bind to HSA to form a fluorescent complex.